Open Door Salon is the life sciences podcast where the people building drug development, biotech investment and healthcare innovation talk on the record. Host Lori Ellis sits down with biotech and pharma executives, investors and regulators for unscripted conversations about what it takes to get new therapies to patients. Change starts with conversation.
How Health Systems Decide Which AI to Buy | Paul Uhrig & Eddie Qureshi
Paul Uhrig is a healthcare lawyer and digital health executive, formerly Chief Legal and Digital Health Officer at Bassett Healthcare Network and Chief Administrative, Legal and Privacy Officer at Surescripts. Eddie Qureshi is founder and CEO of Rainfall Health, an AI platform that helps hospitals manage Medicare's TEAM model.
They explain what health system executives ask before they buy AI, why so many pilots never reach scale, and why only two or three priorities ever make a C-suite agenda. Then the patient side: people connecting their medical records to ChatGPT and Claude, why that data falls outside HIPAA, the consent screens nobody reads, the 30 days after surgery, and why ambient listening stuck with clinicians.
(00:00) The consent form nobody reads
(01:55) AI, bad actors and the threat closer to home
(04:13) Cybersecurity and the 100% landing rule
(07:14) What executives ask before they buy AI
(09:00) Why pilots fail to scale
(10:31) Pitch versus pain point
(14:54) Is every health system the same?
(16:56) Patients bring AI to the exam room
(20:19) Patient data in consumer AI tools
(23:29) HIPAA, the FTC and who educates patients
(26:56) The 30 days after surgery
(31:21) 85% of health systems use AI
(32:02) Why ambient listening stuck
(35:43) What inspired their career paths
(39:01) The hardest decision or challenge
7 Oct 2026
What Cell and Gene Therapy Investors Need to See First | Phil Vanek & David Crean
Phil Vanek, PhD, is Chief Commercialization Officer of the International Society for Cell & Gene Therapy (ISCT), chair of the CGT Catapult Technology Advisory Board and founder of Redline Bioadvisors. David H. Crean, PhD, MBA, is founder and managing partner of Cardiff Advisory and the author of Dual Fluency.
They explain what a cell and gene therapy founder has to show before an investor conversation goes anywhere: a de-risked asset, evidence the biology is real, and a manufacturing plan that is not left to the appendix. They argue for writing the target product profile first, rank capital, reimbursement and manufacturing cost, compare how the US, the UK and Europe pay for advanced therapies, and explain why deals announced at JPM start many months earlier.
(00:00) What founders have to show before the conversation starts
(05:12) Target product profile: write the label first
(09:53) Show me the data: AI, fabricated evidence, and the three pillars ranked
(14:37) Who pays: reimbursement in the US, UK and Europe
(19:16) The four-legged stool and the aducanumab lesson
(25:10) Should you build to be acquired? Who really picks the asset
(31:40) Why JPM deals start nine months earlier
(36:06) Hardening the supply chain, and why science needs capital fluency
(40:56) Career lessons, and killing a program that works
(46:02) Mentorship and advice for emerging founders
30 Sept 2026
Is Your Biotech a National Security Target? | Chad Raduege
Retired Air Force Brigadier General Chad Raduege spent 29 years in communications, IT and cyber operations, commanded the White House Communications Agency, and finished his career as Director of C4/Cyber and CIO for U.S. European Command. Today he is President of Cyber, Data & Communications at Elara Nova.
He explains why he sees biopharma data as a national security matter, how ransomware differs from espionage by advanced persistent threats, and why the CEO owns cyber risk at a 40-person biotech with no CISO. He describes what an adversary could learn from a venture firm's due diligence files, how he reads the summer's incidents at Amgen, Boston Scientific and McKesson, and why the industry should build security in and share what it learns.
(00:00) First to market, first breached, and meet Chad Raduege
(05:36) Taking the Oval Office anywhere: the White House Communications Agency
(09:45) EUCOM: Afghanistan, COVID and Russia's invasion of Ukraine
(14:24) Where biopharma sits on a nation-state target list
(19:17) Ransomware vs. espionage, and the 40-person biotech with no CISO
(25:50) VC diligence files, accountability and crown jewels
(33:14) Amgen, Boston Scientific, McKesson: an adversary mapping the industry
(37:40) Build it in, don't strap it on, and the path to 29 years
(43:59) Stop casting stones: ISACs and learning together
Reach and audience
Public platform figures. Ratings count people who left a rating, not total listeners.
Apple Podcasts (US)
5.0 / 5
1 ratings
Spotify
5.0 / 5
2 ratings
Contact Open Door Salon
Guest appearances
Books guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Host of Open Door Salon?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
